ArticleiScience2021
Learning from HIV-1 to predict the immunogenicity of T cell epitopes in SARS-CoV-2.
Article in iScience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Central T cell tolerance from sparse peptide sampling.Science advances · 2026Article
- Design of an immunogen containing multidimensionally conserved and immunogenic parts of the HIV proteome.PLoS computational biology · 2026Article
- Impaired and restored CD8Frontiers in immunology · 2025Article
- Article
- A journey to your self: The vague definition of immune self and its practical implications.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Transfer learning improves pMHC kinetic stability and immunogenicity predictions.Immunoinformatics (Amsterdam, Netherlands) · 2024Article
- Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8Immunity · 2023Article
- Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants.Bioengineering (Basel, Switzerland) · 2023Review
- Dissecting Naturally Arising Amino Acid Substitutions at Position L452 of SARS-CoV-2 Spike.Journal of virology · 2022Article
- The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition.Nature communications · 2022Article
- The biological and clinical significance of emerging SARS-CoV-2 variants.Nature reviews. Genetics · 2021Review
- SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity.Cell host & microbe · 2021Article
Corrections and comments
- Update of
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
Abstract
We describe a physics-based learning model for predicting the immunogenicity of cytotoxic T lymphocyte (CTL) epitopes derived from diverse pathogens including SARS-CoV-2. The model was trained and optimized on the relative immunodominance of CTL epitopes in human immunodeficiency virus infection. Its accuracy was tested against experimental data from patients with COVID-19. Our model predicts that only some SARS-CoV-2 epitopes predicted to bind to HLA molecules are immunogenic. The immunogenic CTL epitopes across all SARS-CoV-2 proteins are predicted to provide broad population coverage, but those from the SARS-CoV-2 spike protein alone are unlikely to do so. Our model also predicts that several immunogenic SARS-CoV-2 CTL epitopes are identical to seasonal coronaviruses circulating in the population and such cross-reactive CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.